SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-490689"
 

Sökning: id:"swepub:oai:DiVA.org:uu-490689" > COVID‐19 outcomes i...

  • Lim, Yeong JerHaemato‐oncology Department Clatterbridge Cancer Centre NHS Foundation Trust Liverpool UK;Institute of Systems, Molecular and Integrative Biology University of Liverpool Liverpool UK (författare)

COVID‐19 outcomes in haematopoietic cell transplant recipients : A systematic review and meta‐analysis

  • Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

  • 2022-06-14
  • USA :John Wiley & Sons,2022
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-490689
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-490689URI
  • https://doi.org/10.1002/jha2.465DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Up-to-date information on coronavirus disease 2019 (COVID-19) outcomes and risk factors in haematopoietic cell transplantation (HCT) recipients is required to inform on decisions about cancer treatment and COVID-19 mitigation strategies. We performed a meta-analysis to address this knowledge gap. All studies with at least five patients who reported COVID-19-related deaths in HCT recipients were included. The primary outcome was COVID-19-related death. Secondary outcomes were COVID-19-related mechanical ventilation (MV) and intensive care unit (ITU) admission. The cumulative COVID-19-related death rate among HCT recipients was 21% (95% confidence interval [CI] 18%–24%), while MV and ITU admission rates were 14% (95% CI 11%–17%) and 18% (95% CI 14%–22%), respectively. Subgroup analysis showed higher death rates in patients who developed COVID-19 within 12 months of HCT (risk ratio [RR] 1.82, 95% CI 1.09–3.03), within 6 months of receiving immunosuppressant drugs (RR 2.11, 95% CI 1.38–3.20) or in the context of active graft-versus-host disease (RR 2.38, 95% CI 1.10–5.16). Our findings support the idea that HCT should remain an integral part of cancer treatment during the COVID-19 pandemic but also highlight the need to prioritise preventative measures in those patients who are at increased risk of adverse COVID-19 outcomes.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Khan, UmairHaemato‐oncology Department Clatterbridge Cancer Centre NHS Foundation Trust Liverpool UK;Institute of Systems, Molecular and Integrative Biology University of Liverpool Liverpool UK (författare)
  • Karpha, IndraniHaemato‐oncology Department Clatterbridge Cancer Centre NHS Foundation Trust Liverpool UK;Institute of Systems, Molecular and Integrative Biology University of Liverpool Liverpool UK (författare)
  • Ross, AndrewHaemato‐oncology Department Clatterbridge Cancer Centre NHS Foundation Trust Liverpool UK (författare)
  • Saif, MuhammadHaemato‐oncology Department Clatterbridge Cancer Centre NHS Foundation Trust Liverpool UK (författare)
  • Remberger, Mats,Professor,1955-Uppsala universitet,Institutionen för medicinska vetenskaper,KFUE, Uppsala University Hospital, Uppsala, Sweden(Swepub:uu)matre804 (författare)
  • Kalakonda, NageshHaemato‐oncology Department Clatterbridge Cancer Centre NHS Foundation Trust Liverpool UK;Institute of Systems, Molecular and Integrative Biology University of Liverpool Liverpool UK (författare)
  • Pettitt, Andrew R.Haemato‐oncology Department Clatterbridge Cancer Centre NHS Foundation Trust Liverpool UK;Institute of Systems, Molecular and Integrative Biology University of Liverpool Liverpool UK (författare)
  • Floisand, YngvarHaemato‐oncology Department Clatterbridge Cancer Centre NHS Foundation Trust Liverpool UK;Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine University of Oslo Oslo Norway (författare)
  • Haemato‐oncology Department Clatterbridge Cancer Centre NHS Foundation Trust Liverpool UK;Institute of Systems, Molecular and Integrative Biology University of Liverpool Liverpool UKHaemato‐oncology Department Clatterbridge Cancer Centre NHS Foundation Trust Liverpool UK (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:eJHaemUSA : John Wiley & Sons3:3, s. 862-8722688-6146

Internetlänk

Hitta via bibliotek

  • eJHaem (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy